NCT02682667Recruiting
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments. Objective: To better understand the biology of malignancies and why certain cancers respond differently to treatment. Eligibility: Adults at least 18 years old with cancer or a pre-cancerous condition. Design: Participants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology. Participants will send tissue blocks or slides from their original tumor biopsy. At least once, participants will have a medical history, physical exam, and blood and urine tests. Participants may have the following tests. They may have them more than once: Apheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm. Bone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle. Piece of cancer tissue taken by a needle and syringe. Computed tomography (CT) scan, magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures. A small piece of skin removed. Participants will be contacted by phone once a year to find out how they are doing. ...
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 10 Feb 2016
- Start date
- 11 Apr 2016
- Primary completion date
- 1 Dec 2030
- Lead sponsor
- National Cancer Institute (NCI)
- Diseases
- Hodgkin lymphoma, Lung cancer, Multiple myeloma
- NCT number
- NCT02682667
What you commit to
- Study type: Observational
- Planned participants: 500
- From 11 Apr 2016 to the primary completion date, 1 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active concomitant medical or psychological illnesses that may increase the risk to the subject.
Other
- Inability to provide informed consent
- Pregnant or breastfeeding women
Criteria the registry did not label
- INCLUSION CRITERIA:
- Diagnosis of cancer, a premalignant/neoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant/neoplastic condition
- Age \>=18 years of age
- ECOG performance status of 0-3.
- 5\. Ability and willingness of subject to provide informed consent
- Additional inclusion criteria pertinent only for participants undergoing apheresis
- Hemoglobin \>= 8 mg/dL and platelet count \> 75 K/microL
- Weight \>= 48 kg
- Central line in place or adequate venous access
Age in the registry: 18 years to 120 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Institutes of Health Clinical Center Coordinator of this site? Confirm its status | Bethesda | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.